Brain‑derived neurotrophic factor exerts neuroprotective actions against amyloid β‑induced apoptosis in neuroblastoma cells

Kim,Jin  Hee

doi:10.3892/etm.2014.2033

Brain‑derived neurotrophic factor exerts neuroprotective actions against amyloid β‑induced apoptosis in neuroblastoma cells

Authors:
- Jin Hee Kim
View Affiliations

Affiliations: Department of Neurosurgery, College of Medicine, Korea University, Seoul 136-701, Republic of Korea
Published online on: October 17, 2014 https://doi.org/10.3892/etm.2014.2033
Pages: 1891-1895

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Alzheimer's disease (AD) brains demonstrate decreased levels of brain‑derived neurotrophic factor (BDNF) and increased levels of β‑amyloid peptide (Aβ), which is neurotoxic. The present study assessed the impact of BDNF on the toxic effects of Aβ25‑35‑induced apoptosis and the effects on BDNF‑mediated signaling using the MTT assay, western blotting and reverse transcription quantitative polymerase chain reaction. Aβ25‑35 was found to induce an apoptosis, dose‑dependent effect on SH‑SY5Y neuroblastoma cells, which peaked at a concentration of 20 µM after 24 h. A combination of Aβ25‑35 and BDNF treatment increased the levels of Akt and decreased the level of glycogen synthase kinase‑3β (GSK3β) in SH‑SY5Y neuroblastoma cells. These findings indicated that BDNF administration exerted a neuroprotective effect against the toxicity of the Aβ25‑35‑induced apoptosis in these cells, which was accompanied by phosphoinositide 3‑kinase/Akt activation and GSK3β phosphorylation. The mechanisms and signaling pathways underlying neuronal degeneration induced by the Aβ peptide remain to be further elucidated.

View Figures

View References

1	Mesulam MM: Neuroplasticity failure in Alzheimer’s disease: bridging the gap between plaques and tangles. Neuron. 24:521–529. 1999.
2	Dickson DW: Neuropathology of Alzheimer’s disease and other dementias. Clin Geriatr Med. 17:209–228. 2001.
3	Song B, Davis K, Liu XS, Lee HG, Smith M and Liu X: Inhibition of Polo-like kinase 1 reduces beta-amyloid-induced neuronal cell death in Alzheimer’s disease. Aging (Albany NY). 3:846–851. 2011.PubMed/NCBI
4	Selkoe DJ: Alzheimer’s disease is a synaptic failure. Science. 298:789–791. 2002.
5	Yankner BA: Mechanisms of neuronal degeneration in Alzheimer’s disease. Neuron. 16:921–932. 1996.
6	Götz J and Ittner LM: Animal models of Alzheimer’s disease and frontotemporal dementia. Nat Rev Neurosci. 9:532–544. 2008.
7	Poo MM: Neurotrophins as synaptic modulators. Nat Rev Neurosci. 2:24–32. 2001. View Article : Google Scholar : PubMed/NCBI
8	Lindvall O, Kokaia Z, Bengzon J, Elmér E and Kokaia M: Neurotrophins and brain insults. Trends Neurosci. 17:490–496. 1994. View Article : Google Scholar : PubMed/NCBI
9	Lewin GR and Barde YA: Physiology of the neurotrophins. Annu Rev Neurosci. 19:289–317. 1996. View Article : Google Scholar
10	Cross DA, Alessi DR, Cohen P, Andjelkovich M and Hemmings BA: Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 378:785–789. 1995. View Article : Google Scholar : PubMed/NCBI
11	Sun L, Guo C, Liu D and Zhao Y, Zhang Y, Song Z, Han H, Chen D and Zhao Y: Protective effects of bone morphogenetic protein 7 against amyloid-beta induced neurotoxicity in PC12 cells. Neuroscience. 184:151–163. 2011. View Article : Google Scholar : PubMed/NCBI
12	Abràmoff MD, Magalhães PJ and Ram SJ: Image processing with ImageJ. Biophotonics International. 11:36–42. 2004.
13	Zhao R, Zhang Z, Song Y, Wang D, Qi J and Wen S: Implication of phosphatidylinositol-3 kinase/Akt/glycogen synthase kinase-3β pathway in ginsenoside Rb1’s attenuation of beta-amyloid-induced neurotoxicity and tau phosphorylation. J Ethnopharmacol. 133:1109–1116. 2011.PubMed/NCBI
14	Amtul Z, Uhrig M and Beyreuther K: Additive effects of fatty acid mixtures on the levels and ratio of amyloid β40/42 peptides differ from the effects of individual fatty acids. J Neurosci Res. 89:1795–1801. 2011.PubMed/NCBI
15	Hongpaisan J, Sun MK and Alkon DL: PKC ɛ activation prevents synaptic loss, Aβ elevation, and cognitive deficits in Alzheimer’s disease transgenic mice. J Neurosci. 31:630–643. 2011.
16	Kaminsky YG, Marlatt MW, Smith MA and Kosenko EA: Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25–35). Exp Neurol. 221:26–37. 2010.PubMed/NCBI
17	Peng S, Wuu J, Mufson EJ and Fahnestock M: Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer’s disease. J Neurochem. 93:1412–1421. 2005.PubMed/NCBI
18	Laske C, Stransky E, Leyhe T, Eschweiler GW, Maetzler W, Wittorf A, Soekadar S, Richartz E, Koehler N, Bartels M, Buchkremer G and Schott K: BDNF serum and CSF concentrations in Alzheimer’s disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res. 41:387–394. 2007.
19	Murer MG, Boissiere F, Yan Q, Hunot S, Villares J, Faucheux B, Agid Y, Hirsch E and Raisman-Vozari R: An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer’s disease. Neuroscience. 88:1015–1032. 1999.PubMed/NCBI
20	Koide H, Asai T, Furuya K, Tsuzuku T, Kato H, Dewa T, Nango M, Maeda N and Oku N: Inhibition of Akt (ser473) phosphorylation and rapamycin-resistant cell growth by knockdown of mammalian target of rapamycin with small interfering RNA in vascular endothelial growth factor receptor-1-targeting vector. Biol Pharm Bull. 34:602–608. 2011. View Article : Google Scholar
21	Mannoury la Cour C, Salles MJ, Pasteau V and Millan MJ: Signaling pathways leading to phosphorylation of Akt and GSK-3β by activation of cloned human and rat cerebral D₂ and D₃ receptors. Mol Pharmacol. 79:91–105. 2011.
22	Sánchez-Blázquez P, Rodríguez-Muñoz M and Garzón J: Mu-opioid receptors transiently activate the Akt-nNOS pathway to produce sustained potentiation of PKC-mediated NMDAR-CaMKII signaling. PLoS One. 5:e112782010.PubMed/NCBI
23	Soriano FX, Papadia S, Hofmann F, Hardingham NR, Bading H and Hardingham GE: Preconditioning doses of NMDA promote neuroprotection by enhancing neuronal excitability. J Neurosci. 26:4509–4518. 2006. View Article : Google Scholar : PubMed/NCBI
24	Grimes CA and Jope RS: The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol. 65:391–426. 2001. View Article : Google Scholar : PubMed/NCBI
25	Beaulieu JM, Gainetdinov RR and Caron MG: Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol. 49:327–347. 2009. View Article : Google Scholar : PubMed/NCBI